IP Library Granted Patent US 10,260,047
Granted Patent B2
US 10,260,047 · App. 14/955,760 · Granted Apr 16, 2019

Angiohematopoietic progenitor cells

Inventors: Igor I. Slukvin (Verona, WI); Maksym A. Vodyanyk (Madison, WI); Kyung-Dal Choi (Falcon Heights, MN)
Assignee: Wisconsin Alumni Research Foundation
C12N5/0692A61K35/28C12N5/0647G01N33/502G01N33/5073A61K2035/124C12N2502/1394C12N2506/02C12N2506/45
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,260,047
App. No.
14/955,760
Granted
Apr 16, 2019
Kind
B2
Abstract

A purified human cell population of subsets of angiohematopoietic progenitor cells, wherein the population is at least 94% pure and wherein the cells are selected with cell markers selected from the group of KDR, APLNR, VE-cadherin, PDGFRα, CD31, CD235a, CD73, CD43, and CD41a.

Claims (8)

1. A cell population, comprising:

a purified population of human hemogenic endothelial progenitors, which express VE-cadherin, but do not express CD73, CD235a, and CD43; and a population of OP-9 stromal cells, wherein the progenitors were generated from human pluripotent stem cells wherein the OP-9 stromal cells induced hematoendothelial differentiation of the pluripotent stem cells, and wherein the purified population of human hemogenic endothelial progenitors is at least 94% pure.

2. The cell culture of claim 1 comprising a purified population of the human hemogenic endothelial progenitors which express VE-cadherin, but do not express CD73, CD235a, and CD43 wherein the purified population is at least 98% pure.

3. A cell population, comprising:

a 94% pure population of human hemogenic endothelial progenitors, which express VE-cadherin, but do not express CD73, CD235a, and CD43 wherein the progenitors are obtained by a method comprising the steps of:

a) culturing pluripotent stem cells with OP9 stromal cells so that hematoendothelial differentiation occurs, and

b) sorting the cultured cells of step a) by cell markers selected from the group consisting of VE-cadherin, CD31, CD235a, CD73, CD43 and CD41 a such that a 94% purified cell population of human hemogenic endothelial progenitors is obtained.

4. The cell population of claim 3 , wherein the cell population is 98% pure population of human hemogenic endothelial progenitors.

Assignments (2)
CONFIRMATORY LICENSE Recorded May 24, 2018
From: UNIVERSITY OF WISCONSIN-MADISON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046233/0887 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2016
From: SLUKVIN, IGOR; VODYANYK, MAKSYM; CHOI, KYUNG-DAL
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 039097/0457 →
Continuity (3)
Continuation 13590591 · Aug 21, 2012
Provisional Application 61526520 · Aug 23, 2011
Related Publication 20160194610A1 · Jul 7, 2016